← Leaderboards
John R Murren
Yale University
$1,132,319
Attributed
$1,132,319
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,132,319 · 6
By mechanism
R21$879,630 · 2
R01$202,549 · 1
M01$50,140 · 3
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Joseph N Contessa$6,133,778
- Don X Nguyen$10,390,286
- Abhijit Patel$5,506,607
- Katerina Abigail Politi$13,632,706
- Cary P Gross$11,062,635
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationNeoplasm /Cancer ChemotherapyAntineoplasticsPharmacokineticsClinical Trial Phase IDosageDrug Screening /EvaluationDrug Adverse EffectCombination ChemotherapyDrug ResistanceIrinotecanPatient Oriented ResearchTopotecanCytotoxicityCamptothecinProteasomeGene ExpressionNeoplasm /Cancer GeneticsAminopyridinesNeoplasm /Cancer PharmacologyNeoplasm /Cancer Relapse /RecurrenceClinical Trial Phase Ii
Grant awards (9)
COMBINATION OF TOPOTECAN AND PS-341 IN TREATMENT OF ADVANCED MALIGNANCIES$3,970
M01 · FY2005 · RR
Improved Use of Camptothecins for Small Cell Lung Cancer$294,300
R21 · FY2004 · CA
Dose Finding Phase I Trial of Combination of Topetecan a$11,635
M01 · FY2004 · RR
Improved Use of Camptothecins for Small Cell Lung Cancer$294,300
R21 · FY2003 · CA
Radioisotope Therapy Targeting the Somatostatin Receptor$291,030
R21 · FY2002 · CA
3-aminopyridine-2-carbozaldehyde thiosemicarbazone (3AP) in cancer$0
M01 · FY2001 · RR
BIOCHEMICAL STUDIES OF ACQUIRED CHEMOTHERAPY RESISTANCE$202,549
R01 · FY2000 · CA
PHASE I STUDY OF PERILLYL ALCOHOL IN PATIENTS WITH REFRACTORY MALIGANCIES$34,535
M01 · FY2000 · RR
3-aminopyridine-2-carbozaldehyde thiosemicarbazone (3AP) in cancer$0
M01 · FY2000 · RR